Business and Finance

Implications for pharma are in continuing pricing pressure, and preferences for distribution channels

Action adds to the increasing number of global healthcare-distribution pathways

Although controversial, patient-focused discounts can play a valuable role in managed-markets programs

While 78% of survey respondents will "demand clear proof of cost savings" to ensure formulary placement, 44% of them have "little or no confidence" in the economic arguments presented by pharmacos

Dohmen pioneers an integrated, 'conflict free' pharmaceutical services company

The leading chain pharmacy steps up its role as healthcare provider and partner to pharma

Biopharma remains a bright spot in US and international economic activity, even while the overall outlook remains cloudy

Latest annual Progressions report highlights the shift to healthy behaviors

Patient office visits, prescription usage continued to decline

Covis Pharmaceuticals' business model is to acquire distribution rights to low-volume drugs

Applying a consistent framework to choose locations can help optimize R&D and drive cost reduction for pharmaceutical companies of all sizes

Pharmaceutical Commerce sat down with Chris Smith, president and COO; here's what he had to say.

Buys marketing rights to networks of independent pharmacies for C$920 million

White paper points out the drop in pipeline performance; suggests a new direction is necessary

Taking a market-by-market approach to maximizing value after loss of exclusivity

Small changes in contract terms can have large consequences in net revenue

Life sciences CFOs can address growing cost pressures through decision support centralization

Recognizing the realities of how new product launches enter the market

Regional pharmacy benefit manager is on a growth curve

CLM Matrix system exploits Microsoft SharePoint platform

Generics claim 78% of US market; prescriptions dispensed were up slightly, but doctor visits declined in 2010

Cost dominates the payer and physician perspective, manufacturers look to outcomes, while patients see little value in outcomes